METHODS	From June 2009 to July 2010 , 1,332 people with type 2 diabetes and other cardiovascular risk factors aged 50 years whose HbA ( 1c ) was 6.5-9 .5 % ( 48-80 mmol/mol ) when using two or fewer glucose-lowering drugs were randomised by a central computer system to placebo ( n = 541 ) , rosiglitazone 4-8 mg/day ( n = 399 ) or pioglitazone 30-45 mg/day ( n = 392 ) ; 1,221 participants were randomised to placebo ( n = 614 ) or vitamin D 1,000 IU/day ( n = 607 ) .\